
Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug.

Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug.
News round-up for 9 – 13 February by Bruno Quinney, Content Team at DDW. This week in DDW, researchers have…
California Walnut كما أظهر بحثٌ جديد أن تناول الجوز في وجبة الإفطار يمكن أن يحسّن…
Arab Newswire - Press release distribution to media in MENA/GCC Regions Newswire expands reach with…
The advisory committee, which met after the agency rolled out new vaccine guidelines, said companies should tailor their booster doses…
News Ginkgo Bioworks has introduced the Virtual Cell Pharmacology Initiative (VCPI) through its Ginkgo Datapoints division, creating what it describes…
Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in…
News Flatiron Health has launched six new hematology datasets built using AI and large language models (LLMs), unlocking longitudinal clinical…
Sign in to your account